We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest close session, CVS Health (CVS - Free Report) was down 1.98% at $73.50. The stock trailed the S&P 500, which registered a daily gain of 0.47%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq added 0.94%.
Shares of the drugstore chain and pharmacy benefits manager witnessed a gain of 9.3% over the previous month, beating the performance of the Medical sector with its gain of 5.49%, and the S&P 500's gain of 2.32%.
The upcoming earnings release of CVS Health will be of great interest to investors. On that day, CVS Health is projected to report earnings of $1.36 per share, which would represent year-over-year growth of 24.77%. Meanwhile, our latest consensus estimate is calling for revenue of $97.96 billion, up 2.65% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and a revenue of $391.11 billion, representing changes of +16.97% and +4.91%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.34% rise in the Zacks Consensus EPS estimate. At present, CVS Health boasts a Zacks Rank of #3 (Hold).
From a valuation perspective, CVS Health is currently exchanging hands at a Forward P/E ratio of 11.82. This indicates a discount in contrast to its industry's Forward P/E of 16.7.
We can additionally observe that CVS currently boasts a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.5.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 41% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Stock Dips While Market Gains: Key Facts
In the latest close session, CVS Health (CVS - Free Report) was down 1.98% at $73.50. The stock trailed the S&P 500, which registered a daily gain of 0.47%. Elsewhere, the Dow gained 0.11%, while the tech-heavy Nasdaq added 0.94%.
Shares of the drugstore chain and pharmacy benefits manager witnessed a gain of 9.3% over the previous month, beating the performance of the Medical sector with its gain of 5.49%, and the S&P 500's gain of 2.32%.
The upcoming earnings release of CVS Health will be of great interest to investors. On that day, CVS Health is projected to report earnings of $1.36 per share, which would represent year-over-year growth of 24.77%. Meanwhile, our latest consensus estimate is calling for revenue of $97.96 billion, up 2.65% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and a revenue of $391.11 billion, representing changes of +16.97% and +4.91%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.34% rise in the Zacks Consensus EPS estimate. At present, CVS Health boasts a Zacks Rank of #3 (Hold).
From a valuation perspective, CVS Health is currently exchanging hands at a Forward P/E ratio of 11.82. This indicates a discount in contrast to its industry's Forward P/E of 16.7.
We can additionally observe that CVS currently boasts a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.5.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 41% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.